A First-in-human Dose Escalation and Expansion Trial With the Antibody-drug Conjugate BYON4413 to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms.
Latest Information Update: 06 Apr 2026
At a glance
- Drugs BYON 4413 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Byondis
Most Recent Events
- 20 Jan 2026 Actual Primary Completion Date is 30 Sep 2025.
- 20 Jan 2026 Planned End Date changed from 1 Mar 2027 to 1 Feb 2026.
- 20 Jan 2026 Status changed from recruiting to active, no longer recruiting.